Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention.
Options
BORIS DOI
Publisher DOI
PubMed ID
34339764
Description
In many countries worldwide, the burden of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing and preventive strategies are needed to counteract this trend. This review provides an overview of the evidence on preventive strategies in NAFLD-associated HCC. We considered the impact of lifestyle factors such as weight loss, physical activity, smoking, dietary patterns and food items, including coffee and alcohol, on both HCC and NAFLD/NASH. Furthermore, evidence on chemopreventive treatments, including aspirin, anti-diabetic treatments and statins is summarized. The role of adjuvant therapies considered for tertiary prevention of HCC is briefly reviewed.
Date of Publication
2021-11
Publication Type
Article
Subject(s)
600 - Technology::610 - Medicine & health
Keyword(s)
Non-alcoholic fatty liver disease (NAFLD) Nonalcoholi steatohepatitis (NASH) aspirin coffee hepatocellular carcinoma (HCC) lifestyle metformin prevention statins
Language(s)
en
Additional Credits
Universitätsklinik für Viszerale Chirurgie und Medizin
Universitätsklinik für Viszerale Chirurgie und Medizin, Hepatologie
Series
Journal of hepatology
Publisher
Elsevier
ISSN
0168-8278
Access(Rights)
open.access